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Introduction
Tuberculosis (TB), a progressive disease that takes one
human life approximately every 15 seconds globally, is
caused by invasion of macrophages by Mycobacterium
tuberculosis. The use of Bacillus Calmette-Guerin (BCG) as
a protective vaccine for TB is questionable as it provides
only 50% protection in pulmonary TB and is not effective
in adults.1 In addition to the problem of its limited protec-
tive value, use of BCG in immunocompromised individu-
als with human immunodeficiency virus (HIV) infection
or acquired immune deficiency syndrome (AIDS) can
cause disseminated disease.2–5 Secretory proteins (culture
filtrate proteins) of the bacterium are recognized directly
by the host immune system, and some of these, such as
Ag-85, MPT-64, MPB-70, culture filtrate protein (CFP)-10
and early secreted antigenic target-6 (ESAT-6), are promis-
ing subunit vaccine candidates for vaccination against
TB.6–8 Although several vaccine candidates are under
development, a better vaccine which could provide long-
term protection against TB is unlikely to be developed in
the near future.9
Protection against M. tuberculosis infection requires
activation of both innate and adaptive immunity.10 Acti-
vated T cells mainly restrict progression of TB in the
host.2 Effective activation of T cells depends on the inter-
action of various T-cell receptors (TCRs) (e.g. CD28 and
CD40L) with their counterparts [major histocompatibility
complex (MHC)–peptide complex, B7 molecules and
CD40] on antigen-presenting cells (APCs).11,12 Host resis-
tance to M. tuberculosis infection is governed by the secre-
tion of pro-inflammatory cytokines against M. tuberculosis
invasion and the balance with inhibitory or suppressive
cytokines such as interleukin (IL)-10 and transforming
growth factor (TGF)-b. Host pro-inflammatory cytokines
such as interferon (IFN)-c, tumour necrosis factor
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Summary
Secretory proteins of Mycobacterium tuberculosis are the major immuno-
modulators of the host immune response. Open reading frame (ORF)
Rv2626c, encoding a conserved hypothetical protein eliciting a strong
humoral immune response in patients with tuberculosis (TB), was shown
to be up-regulated upon infection in mice under hypoxic conditions. We
now show that recombinant Rv2626c protein (rRv2626c) can bind to the
surface of murine macrophages and elicit the type-1 immune response, as
manifested by nitric oxide (NO) secretion and expression of inducible
nitric oxide synthase (iNOS). Significant induction of pro-inflammatory
cytokines [interleukin (IL)-12 and tumour necrosis factor (TNF)-a] was
evident upon stimulation of murine macrophages, as well as peripheral
blood mononuclear cells (PBMCs) isolated from patients with active TB
disease, with rRv2626c. Stimulation with rRv2626c also enhanced the
expression of costimulatory molecules such as B7-1, B7-2 and CD40 on
murine macrophages. We further show that the production of NO and
pro-inflammatory cytokines in response to rRv2626c is mediated by the
transcription factor nuclear factor (NF)-jB, and this was further con-
firmed using pyrrolidine dithiocarbamate (PDTC), a specific pharmacolog-
ical inhibitor of NF-jB. Rv2626c therefore appears to modulate
macrophage effector functions by eliciting both innate and adaptive
immune responses, suggesting its possible use as a vaccine candidate.
Keywords: M. tuberculosis; innate and adaptive responses; Rv2626c; vaccine
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(TNF)-a and IL-12 are important resistance factors
against TB.13–17 Pro-inflammatory gene knockout mice
were found to be susceptible to TB infection, indicating a
direct role of these cytokines in immunity to TB.18,19
In addition to the pro-inflammatory cytokines, produc-
tion of nitric oxide (NO) by macrophages is an effective
host defence mechanism against M. tuberculosis. Up-regu-
lation of the expression of inducible nitric oxide synthase
(iNOS) was found to be an important component of host
defence against M. tuberculosis.20 NO exhibits efficient
microbicidal activity even at concentrations < 100 ppm,
killing 99% of M. tuberculosis in culture.21 The impor-
tance of NO in providing protection against TB is clear
from experiments in iNOS knockout mice, which showed
higher mortality and increased dissemination.20 A wide
variety of cytokines and inflammatory mediators such as
TNF-a, IFN-c, lipopolysaccharide (LPS) and IL-1b are
known to induce iNOS expression.22 Several M. tuberculo-
sis components, such as lipoarabinomannan (LAM),23
ESAT-6 antigen,24 and M. tuberculosis-specific antigen
(MTSA) or CFP-10,25 can also stimulate macrophages to
release NO. Many mycobacterial products, such as lipo-
mannan (LM), dimannosylated phosphatidylinositides
(e.g. PIM2), mycolyl arabinogalactan–peptidoglycan com-
plex, phospholipase C and lipoproteins, also have the
potential to induce iNOS expression.23,26
The hypothetical protein coded by M. tuberculosis open
reading frame (ORF) Rv2626c has been shown to elicit a
high serum antibody response in patients with active TB,
suggesting that this antigen is important in immunopro-
filing of disease states.27 Rv2626c expression was up-regu-
lated in hypoxic conditions28 and found in culture
filtrates as well as in lysates in peptide mass fingerprinting
and immune detection studies using an in vitro latency
model. 29 Further studies in mice showed increased
expression of Rv2626c at the terminal stages of infection
in the lungs. Rv2626c and other M. tuberculosis ORFs
encoding a-crystallin (acr), Rv2623, sodC, sodA and
fbpB were found to be differentially expressed in IFN-c
deleted mice. An increase in T helper type 1 (Th-1)-medi-
ated immune responses (IFN-c/iNOS induction) corre-
lated well with increased mRNA synthesis of Rv2626c in
M. tuberculosis, suggesting its up-regulation under stress
conditions.30 Studies using real-time reverse transcrip-
tion–polymerase chain reaction (RT-PCR) to monitor
Rv2626c mRNA synthesis just prior to stress-induced
reduction of bacterial multiplication have suggested a role
of Rv2626c as a transcription signature for non-replicat-
ing persistence.30 In another study where the eight DosR
regulon-encoded antigens (Rv1733c, Rv1738, Rv2029c,
Rv2031c, Rv2032, Rv2627c, Rv2628 and Rv2626c) were
analysed for their immunogenicity in BALB/c and C57BL/
6 mice following vaccination with DNA constructs, it
appeared that Rv2626c and Rv2031 could provide strong
humoral and/or cellular Th-1 responses.31 Furthermore,
peripheral blood mononuclear cells (PBMCs) from
M. tuberculosis-infected patients recognize Rv2626c and
induce major Th-1 cytokines such as IFN-c.32 A correla-
tion between increased expression of Rv2626c (and the
other M. tuberculosis ORFs Rv3286c, Rv2031 and Rv3133c)
and phenotypical tolerance of Mycobacterium bovis BCG
to rifampicin and metronidazole under anaerobic growth
conditions has been found.33 In the present study we
describe the immunostimulatory role of the secretory
16-kDa conserved hypothetical protein coded by the
M. tuberculosis ORF Rv2626c. Our study shows that
recombinant Rv2626c (rRv2626c) binds to the surface of
murine macrophages and up-regulates NO production
and iNOS expression. In addition, we report that
rRv2626c induces the expression and secretion of pro-
inflammatory as well as Th-1 type cytokines such as
TNF-a, IL-12 and IFN-c as well as the up-regulation of
various costimulatory molecules such as B7-1, B7-2 and
CD40. We further show that the induction of iNOS
expression and NO production by rRv2626c is mediated
through the nuclear factor (NF)-jB-dependent pathway.
Materials and methods
Cloning, expression and purification of M. tuberculosis
Rv2626c
The ORF encoding the hypothetical protein Rv2626c of
M. tuberculosis was PCR-amplified from the M. tuberculo-
sis H37Rv cosmid library (kindly provided by Dr Stewart
Cole; Institut Pasteur, Paris, France) using a forward pri-
mer (50-GGC ATA TGA CCA CCG CAC GCG ACA TCA
TG-30) and a reverse primer (5CCG CTC GAG GCT
GGC GAG GGC CAT GGG C-30) harbouring NdeI and
XhoI restriction sites (underlined), respectively. The NdeI/
XhoI-digested 432-bp PCR product was cloned in the
expression vector pET23a (Novagen, Merck Chemicals
Ltd, Nottingham, UK). The clones were confirmed by
sequencing with the T7 promoter primer on an Applied
Biosystems Prism 377 DNA sequencer (Biosystems, Foster
City, CA). The Escherichia coli BL21pLys (DE3) strain was
transformed with the pET23a-2626c construct and the
recombinant protein was expressed and affinity-purified
on a Talon Column (Takara Bio, Madison, WI) as
described previously.34 The protein was eluted with
250 mM imidazole in lysis buffer. The elution fractions
were 95% homogenous as analysed on a 10% sodium
dodecyl sulphate–polyacrylamide gel electrophoresis
(SDS–PAGE) gel followed by Coomassie blue staining.
The purified rRv2626c protein was dialysed against
10 mM Tris/100 mM NaCl to remove the imidazole and
quantified using the bicinchoninic acid test (Micro BCA
Protein Assay kit; Pierce, Rockford, IL). The purified
recombinant protein was incubated overnight at 4 with
10% volume/volume (v/v) polymyxin B-agarose beads
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(Sigma-Aldrich St Louis, MO) to remove any endotoxin
contamination. Further evaluation of bacterial endotoxin
was carried out with the amebocyte lysate assay (E-toxate
Kit; Sigma-Aldrich). The purified rRv2626c protein was
stored in small aliquots at )20 and used in further
experiments.
Macrophage binding assay
In order to study cell surface binding of rRv2626c, anti-
body against rRv2626c was generated in BALB/c mice in
the animal facility of Indian Immunological Limited (Hy-
derabad, India). For binding assays, approximately
1 · 106 RAW 2647 macrophages were washed with wash
buffer [phosphate-buffered saline (PBS) with 1% bovine
serum albumin and 001% sodium azide] twice and then
incubated with rRv2626c (10 lg) for various times on ice.
After washing, RAW 2647 macrophages were incubated
with the anti-Rv2626c antibody at 1 : 2500 dilution for
1 hr at 4 followed by incubation with anti-mouse fluo-
rescein isothiocyanate (FITC) conjugate for 40 min at 4.
After a final washing, RAW 2647 macrophages were sus-
pended in sheath fluid and analysed on a fluorescence-
activated cell sorter (FACS) machine (FACS Vantage SE;
Becton Dickinson, San Jose, CA). For control experi-
ments, cells were treated with (i) medium plus anti-
Rv2626c antibody, (ii) 10 lg of rRv2626c protein plus
normal mouse serum (NMS), or (iii) 10 lg of rRv2626c
plus anti-Rv2626c antibody preincubated with recombi-
nant Rv2626c proteins.
Nitrite and cytokine assay
The mouse macrophage cell lines RAW 2647 and J7741
were obtained from the National Centre for Cell Science,
Pune, India and were maintained in Dulbecco’s modified
Eagle’s minimal essential medium (DMEM; Invitrogen,
Grand Island, NY) supplemented with sodium bicarbon-
ate, 10% fetal calf serum (FCS) and 1% antibiotics. For
the NO and cytokine assay, approximately 3 · 105 RAW
2647 or J7741 macrophages were seeded in a 96-well
culture plate (BD, Falcon, San Jose, CA). Cells were stim-
ulated with different concentrations of rRv2626c and
incubated at 37 for 48 hr. The positive control group
received LPS (1 lg/ml) and IFN-c (1 ng/ml). As and
when required, cells were pretreated by adding 10 lM pyr-
rolidine dithiocarbamate (PDTC; Sigma) and incubating
for 1 hr, followed by stimulation with various concentra-
tions of rRv2626c. For NO estimation by the Griess assay,
equal aliquots of the culture supernatants were dispensed
in duplicate into a 96-well culture plate and mixed with
an equal volume of Griess reagent,35 composed of
1% [weight/volume (w/v)] sulphanilamide, 01% (w/v)
napthyl-ethylenediamine hydrochloride and 25% (v/v)
H3PO4. After incubation at room temperature for 5 min,
the absorbance was measured at 540 nm in an Ultra
Microplate Reader (Bio-Tek, Winooski, VT). The concen-
tration of nitrate was interpolated from the NaNO2
standard curve.
TNF-a and IL-12 p40 levels in the culture supernatants
were measured by enzyme immunoassay (EIA) (BD Bio-
sciences Pharmingen, San Diego, CA) as described previ-
ously.36 Standard curves for each cytokine were obtained
using the recombinant standard protein provided by the
manufacturer.
Flow cytometric analysis of B7-1, B7-2 and CD40
expression
RAW 2647 macrophages (2 · 106 cells/well in a six-well
culture plate) were left untreated or treated with 3 lg/ml
of rRv2626c in the absence or presence of LPS and IFN-c.
After 24 hr of incubation, cells were harvested and
washed three times with ice-cold FACS buffer [PBS con-
taining 1% bovine serum albumin (BSA) and 001%
sodium azide] and then re-suspended in FACS buffer and
incubated with anti-mouse B7-1 (clone 1G10; BD Bio-
sciences Pharmingen), anti-mouse B7-2 (clone GL1; BD
Biosciences Pharmingen) and anti-mouse CD40 (clone 3/
23; BD Biosciences Pharmingen). The control group
received isotype control antibody. Cells were washed
again with FACS buffer and incubated with anti-mouse
FITC (Sigma-Aldrich). Flow cytometric analysis was per-
formed (Becton Dickinson, San Jose, CA) and the FACS
data were recorded for 20 000 events for each labelled cell
population. Flow cytometry data analyses were carried
out using CELL QUEST data analysis software (BD Bios-
ciences, San Jose, CA).
Preparation of whole-cell extract
The RAW 2647 macrophages were seeded at a density of
5 · 106 per well in a six-well culture plate and were either
left untreated or pretreated with PDTC for 1 hr followed
by stimulation with either 5 lg of rRv2626c or a
combination of LPS and IFN-c. Cells were harvested and
the whole-cell extract was prepared as described
previously.37 Equal amounts of the protein (30 lg), after
protein estimation using the Micro BCA Protein Assay kit
from each experimental set (namely, stimulated with
rRv2626c, or rRv2626c + LPS or rRv2626c + IFN), were
fractionated on a 10% SDS-PAGE gel under reducing
conditions and transferred onto a nitrocellulose mem-
brane (GE Healthcare, Piscataway, NJ). The membrane
was then incubated with rabbit polyclonal iNOS antibody
(Sigma) followed by anti-rabbit immunoglobulin-horse
radish peroxidase (Ig-HRP) conjugate (Sigma-Aldrich).
Bound enzyme was detected by chemiluminescence
following the manufacturer’s protocol (GE Healthcare,
Piscataway, NJ).
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Nuclear extract
RAW 2647 macrophages were seeded at a density of
5 · 106 per well in a six-well culture plate and either left
untreated or pretreated with PDTC for 1 hr, followed by
stimulation with 5 lg of rRv2626c alone or with a combi-
nation of LPS and IFN-c. Cells were harvested and nuclear
extract was prepared from NP-40 lysed cells.36 Equal
amounts of the protein extracts (50 lg) were fractionated
on a 10% SDS-PAGE gel. The nuclear proteins were
transferred onto a nitrocellulose membrane and incubated
with polyclonal rabbit antibody to NF-jB p50 or NF-jB
p65 (Santa Cruz Biotech, Santa Cruz, CA) followed by
incubation with anti-rabbit Ig-HRP conjugate. Bound
enzyme was detected by chemiluminescence (ECL).
Electrophoretic mobility shift assay (EMSA)
An equal amount of the nuclear extract (10 lg) from each
set (cells stimulated with rRv2626c, or rRv2626c + LPS or
rRv2626c + IFN) was incubated at 37 for 30 min with
1 ng of c-P32-radiolabelled consensus oligodeoxyribonu-
cleotides containing the binding site for NF-jB (50-ttgtta-
caagggactttccgctggggactttccagggaggcgtgg-30; Santa Cruz
Biotech) in a binding buffer [10 mM Tris, pH 75, 50 mM
NaCl, 1 mM ethylenediaminetetraacetic acid (EDTA), 10%
glycerol, 1 lg of poly dIdC, 1 mM dithiothreitol (DTT),
1 mM phenylmethylsulphonyl fluoride (PMSF) and 50 mM
MgCl2]. For competition experiments, 100-fold molar
excess of unlabelled consensus NF-jB or mutant NF-jB
oligos was used to check the specificity of the DNA–pro-
tein complex. The DNA–protein complexes were resolved
by electrophoresis on a 7% native PAGE gel at 4 in 1·
Tris-borate-EDTA (TBE). After electrophoresis, the gel
was dried and exposed to Phosphor Imager screen (Fuji
Film, Tokyo, Japan) at room temperature for 12 hr and
the screen was scanned using the Typhoon system (GE
Healthcare, Piscataway, NJ).
Study using PBMCs derived from patients with active
TB
Patients with TB who participated in this study were diag-
nosed at the Mahaveer Hospital and Research Centre, Hy-
derabad, India; their TB was confirmed by a tuberculin
skin test, radiographic examination, and observation of
acid-fast bacilli in sputum. Healthy controls were
volunteers at the Centre for DNA Fingerprinting and Diag-
nostics who had no clinical symptoms of TB disease. Blood
samples (2–3 ml) were collected from patients with TB
(n = 48) as well as from healthy controls (n = 9), followed
by separation of PBMCs on Ficoll-Histopaque (Sigma-
Aldrich) as described previously.38 PBMCs were plated at a
density of 2 · 105 per well in a 96-well culture plate and
treated with rRv2626c (5 lg/ml) for 72 hr. The culture su-
pernatants were harvested and assayed for cytokines (TNF-
a, IFN-c and IL-12) by EIA as described previously.39 The
institutional ethical committee approved this study.
Statistical analysis
The statistical significance of the results was determined
using Student’s t-test. The results are presented as
mean ± standard deviation (SD).
Results
Expression and purification of recombinant Rv2626c
The 16-kDa recombinant protein coded by Rv2626c was
expressed in the E. coli BL21plys (DE3) strain and purified
using metal affinity chromatography, giving a yield of
10 mg/l culture. The purified rRv2626c when analysed by
SDS–PAGE (Fig. 1) or even after silver staining (data not
shown) did not reveal any major contaminating protein
band. The endotoxin content in the purified recombinant
protein was checked using the amoebocyte lysate assay and
was found to be extremely low (005 pg/lg of protein).
rRv2626c binds to the surface of RAW 2647
macrophages
Previous studies have revealed that Rv2626c is a secretory
protein, indicating that Rv2626c could influence the host
immune response by interacting with macrophage surface
receptors. In order to assess the ability of rRv2626c to
kDa M 1 2 3 4 5 6 7 8
66
43
29
20
10
Figure 1. Purification of recombinant Rv2626c. His-tagged Rv2626c
was over-expressed in the Escherichia coli pLys strain and purified
by Co++-affinity chromatography. Lanes 1–8 show the successive
elution fractions of the recombinant protein. M is the protein molec-
ular size marker. Tris-Tricine sodium dodecyl sulphate–polyacryl-
amide gel electrophoresis (SDS-PAGE) fractionation and subsequent
Coomassie blue staining revealed 99% homogeneity of the purified
recombinant protein.
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bind to the surface of RAW 2647 macrophages, cells were
incubated with 10 lg of rRv2626c for various times and
the bound rRv2626c was investigated using anti-rRv2626c
antibody in a FACS analysis. The binding of rRv2626c
with macrophages could be seen as early as 5–10 min
after the start of incubation, and remained noticeably
high until 60 min (Fig. 2). It could be seen (Fig. 2, brown
curve) that the binding of rRv2626c to macrophages
was inhibited when the cells were incubated with
anti-Rv2626c antibody preincubated with rRv2626c. This
clearly indicates that rRv2626c binds with high affinity
and specificity to the surface of RAW 2647 macrophages.
Similar observations were obtained for phorbol 12-myri-
state 13-acetate (PMA)-differentiated THP-1 macrophages
(data not shown).
rRv2626c activates NO production by macrophages
Having demonstrated binding of Rv2626c to the surface
of murine macrophage cells cultured in vitro, the ability
of rRv2626c to induce NO production via de novo expres-
sion of iNOS in the macrophages was assessed. RAW
2647 macrophages were stimulated with different concen-
trations of rRv2626c protein (Fig. 3a; bars 3, 4 and 5).
Stimulants such as LPS and IFN-c were used as positive
controls (Fig. 3a; bar 2) for NO production and iNOS
expression (Fig. 3b; lane 2) in RAW 2647 macrophages.
NO production increased in RAW 2647 macrophages
with the addition of rRv2626c in a dose-dependent man-
ner (Fig. 3a; bars 3, 4 and 5). Similar observations were
obtained in J7741 macrophages (data not shown). NO
production by the cells was not observed when cells were
stimulated with proteinase K-treated rRv2626c protein
(Fig. 3a; bar 6), indicating that the NO production was
specifically attributable to the presence of rRv2626c and
was not a result of endotoxin contamination in the
protein preparation. This increased NO production corre-
lated well with the increase in iNOS expression in cells
stimulated with rRv2626c (Fig. 3b; lane 3) as compared
with the unstimulated group (Fig. 3b; lane 1). This clearly
indicates that Rv2626c can stimulate macrophages to pro-
duce NO and that this is mediated by iNOS.
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Figure 2. Recombinant Rv2626c (rRv2626c) binds stably to the mur-
ine macrophage surface with high affinity. RAW 264.7 macrophages
were incubated with rRv2626c (3 lg) at 4 for 60 min and with nor-
mal mouse serum or anti-Rv2626c antibody (raised in a mouse), fol-
lowed by incubation with anti-mouse fluorescein isothiocyanate
(FITC) conjugate. The fluorescence was monitored by fluorescence-
activated cell sorter (FACS) analysis.
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Figure 3. Recombinant Rv2626c (rRv2626c) induces nitric oxide
(NO)/inducible nitric oxide synthase (iNOS) in murine macrophages.
(a) The dose-dependent effect of rRv2626c on NO production in
RAW 264.7 macrophages. RAW 264.7 macrophages (3 · 105) were
treated with either rRv2626c or proteinase K (200 ng/ml) treated
rRv2626c for 48 hr and the supernatants were assayed for NO by the
Griess reagent assay. A combination of lipopolysaccharide (LPS)
(1 lg/ml) and interferon (IFN)-c (1 ng/ml) was used as a positive
control. Data represent the mean ± standard deviation (SD) of at least
three triplicate experiments. Statistical significance was determined
using Student’s t-test and the effect was found to be significant at
P < 0001. (b) RAW 2647 macrophages were stimulated with
rRv2626c. The positive control group received LPS plus IFN-c. The
whole-cell extracts were prepared from these cells to measure iNOS
expression by immunoblotting using polyclonal iNOS antibody. Equal
loading of protein was confirmed by Ponceau S stain. The blot repre-
sents one of the three immunoblots showing similar results.
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rRv2626c-induced NO production is mediated by
NF-jB
iNOS expression and NO production are known to be
dominantly regulated by the transcription factor
NF-jB.23,40 Therefore, we first checked whether rRv2626c
activates the NF-jB transcription factor in macrophages.
RAW 2647 macrophages were either left untreated or
treated with rRv2626c (5 lg). The positive control group
received LPS plus IFN-c. Nuclear extracts were prepared
from these cells and the expression of NF-jB was
mounted using an electrophoretic mobility shift assay. It
was observed that stimulation with rRv2626c caused an
increase in the intensity of the NF-jB complex in vitro
compared with the untreated group (Fig. 4a; compare
lane 4 with lane 2) suggesting induced expression of
NF-jB. A similar increase was apparent in cells stimu-
lated with LPS plus IFN-c (lane 3) as compared with the
control (lane 2). The specificity of the DNA–protein
interaction was confirmed by homologous and heterolo-
gous competition during the binding reaction. In the
presence of a 100-fold molar excess of unlabelled wild-
type consensus NF-jB oligonucleotides, the complex
completely disappeared (lane 6) but was unaffected even
in the presence of a 100-fold molar excess of unlabelled
NF-jB mutant oligonucleotides (lane 7) that carried a
mutation in the bases critical for NF-jB binding. To con-
clusively demonstrate the specific involvement of NF-jB,
a nuclear extract prepared from RAW 2647 cells treated
with PDTC, a specific inhibitor of this transcription
factor,41–43 was used in the electrophoretic mobility shift
assay. PDTC treatment was found to inhibit rRv2626c-
induced NF-jB activity (compare lane 5 with lane 4).
The levels of nuclear p50 and p65 subunits of NF-jB
present in rRv2626c-stimulated macrophages were further
confirmed using NF-jB-specific antibody. The immuno-
blotting results again showed increased nuclear transloca-
tion of p50 and p65, indicating that rRv2626c induces
NF-jB activity (Fig. 4b; compare lane 3 with lane 1) in
macrophages, and this was almost comparable to that
induced by LPS plus IFN-c (lane 2). Treatment with
PDTC, as expected, caused a reduction in nuclear trans-
location of both p50 and p65 subunits of NF-jB (lane 4).
Having shown the direct involvement of NF-jB, we
once again assayed for activation of iNOS by western
blotting as well as NO production in the presence or
absence of PDTC followed by stimulation with rRv2626c.
While rRv2626c induced iNOS expression (Fig. 4c; lane
3) comparable to that induced by LPS plus IFN-c
(Fig. 4c; lane 2), treatment with PDTC inhibited
rRv2626c-induced iNOS expression (Fig. 4c; compare lane
4 with lane 3). The subsequent production of NO in these
experimental groups was measured. Again, it was
observed that rRv2626c increased NO production as a
function of concentration (Fig. 4d; bars 2, 3 and 4), and
NO production was inhibited by PDTC treatment
(Fig. 4d; bars 5, 6 and 7) in a concentration-dependent
manner. These observations provide direct evidence that
rRv2626c induces iNOS expression via signalling pathways
associated with NF-jB activation.
rRv2626c activates the pro-inflammatory response in
RAW 2647 cells
A recent study has shown that DNA vaccination with
Rv2626c in infected mice increases levels of Th-1 type
cytokines such as IFN-c and IL-2 and cytotoxic activity
in vivo.31 Th-1 responses are regulated at the level of
IL-12,44,45 and both IL-12 and TNF-a are protective
against TB.46 We therefore checked whether rRv2626c
actually activates macrophages to induce a Th-1 response.
TNF-a as well as IL-12 production was measured in mac-
rophages after treatment with different concentrations of
rRv2626c protein. The culture supernatants were har-
vested after 48 hr and TNF-a and IL-12 production was
measured by EIA as described previously.36,39 It was
observed that treatment with rRv2626c increased produc-
tion of TNF-a (Fig. 5a) and IL-12 (Fig. 5b) as a function
of protein concentration (Fig. 5a,b; compare bars 3, 4
and 5 with bar 1 in both cases). Treatment with LPS
plus IFN-c (bar 2) was used as a positive control. These
results demonstrate that rRv2626c can act as an immuno-
modulator by activating the pro-inflammatory cytokines.
rRv2626c promotes Th-1 response in PBMCs derived
from patients with active TB disease
Having shown the ability of rRv2626c to act as an immu-
nomodulator using in vitro cultured macrophage cell lines
(RAW 2647), we further investigated the immunomodu-
latory effect of Rv2626c on PBMCs isolated from patients
with active TB. This investigation was carried out by
quantifying the levels of various Th-1 type cytokines such
as IFN-c (Fig. 6a), TNF-a (Fig. 6b) and IL-12 (Fig. 6c) in
an EIA using culture supernatants of PBMCs treated with
rRv2626c (5 lg/ml) for 72 hr. It was observed that
rRv2626c was able to increase IL-12, TNF-a and IFN-c
secretion in PBMC cultures from TB patients as com-
pared with those from healthy controls (Fig. 6a,b,c).
These results clearly demonstrate the involvement of
rRv2626c as an immunomodulator when assayed using
PBMCs from patients with active TB.
rRv2626c increases expression of costimulatory
molecules
We next examined whether rRv2626c has any role in the
modulation of macrophage costimulatory molecules,
which are important for the activation of the adaptive
immune response. Therefore, RAW 2647 macrophages
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Figure 4. Recombinant Rv2626c (rRv2626c)-induced nitric oxide (NO) production and inducible nitric oxide synthase (iNOS) expression is
mediated by nuclear factor (NF)-jB. (a) RAW 2647 macrophages were treated with rRv2626c in the absence or presence of pyrrolidine dithio-
carbamate (PDTC) (10 lm). The positive control group received lipopolysaccharide (LPS) plus interferon (IFN)-c. Nuclear extracts prepared
from these cells were used to measure NF-jB activation by electrophoretic mobility shift assay (EMSA). (b) In a different experiment, RAW
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vested to measure NO production by the Griess assay. Data represent the mean ± standard deviation (SD) of three experiments. Statistical signif-
icance was determined using Student’s t-test and the effect was found to be significant at P < 0001.
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were treated with 3 lg/ml rRv2626c protein in the pres-
ence or absence of LPS plus IFN-c and the surface expres-
sion profiles of various costimulatory molecules were
examined after 24 hr by FACS analysis. It was seen that
stimulation with rRv2626c alone was able to up-regulate
the expression of costimulatory molecules such as B7-1,
B7-2 and CD40 (Fig. 7a, b and c) at levels comparable to
those induced by LPS plus IFN-c. Thus, rRv2626c can
influence the antigen-presenting activity of macrophages
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matory cytokine response in RAW 2647 murine macrophage cells in
a dose-dependent manner. RAW 2647 (3 · 105) macrophages were
treated with various concentrations of rRv2626c. The positive control
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feron (IFN)-c. After 48 hr the culture supernatants were harvested
and assayed for tumour necrosis factor (TNF)-a (a) and interleukin
(IL)-12 (b) levels by enzyme immunoassay (EIA). Data represent the
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Statistical significance was determined using Student’s t-test and the
effect was found to be significant at P < 0001.
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Figure 6. Recombinant Rv2626c (rRv2626c) promotes the expression
of T helper type 1 (Th-1) cytokines in peripheral blood mononuclear
cells (PBMCs) isolated from patients with active tuberculosis (TB)
disease. PBMCs (2 · 105) from healthy controls (n = 9) and patients
with TB (n = 48) were stimulated with rRv2626c at a concentration
of 5 lg/ml for 72 hr. Culture supernatants were collected and the
expression of interferon (IFN)-c (a), tumour necrosis factor (TNF)-a
(b) and interleukin (IL)-12 (c) was quantified by enzyme immuno-
assay (EIA). Statistical significance was determined using Student’s
t-test and the effect was found to be significant at P < 0001.
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to prime T cells by directly activating the expression of
these costimulatory molecules.
Discussion
Manipulations of the immune systems of mice with neu-
tralizing antibodies or gene knockouts have provided
strong evidence that anti-mycobacterial immunity corre-
lates with the Th1 immune response. In TB, macrophages
play an important role in controlling the infection by regu-
lating both the innate signalling and the T cell-mediated
Th1/Th2 immune response.47–49 The interaction between T
cells and macrophages is known to be critical for preven-
tion of bacterial growth.50–53 However, it is not clear how
various M. tuberculosis proteins can trigger the Th1
response. Several factors, such as the affinity between the
T-cell receptor (TCR) and peptide–MHC ligand, peptide
ligand density and costimulatory signalling during T-cell
activation, can play important roles in the regulation of the
Th1/Th2 T-cell response.11,12,54–57 Cytokines induced dur-
ing innate activation of macrophages have also been shown
to be extremely important in controlling the Th1/Th2 bal-
ance. For example, induction of IL-12 or TNF-a can trigger
a Th1 response;58,59 however, if more IL-10 is produced,
the response is likely to be biased towards the Th2 type
response.60,61 It has been shown that various M. tuberculo-
sis secretory proteins bind to a specific receptor on macro-
phages and influence the downstream signalling cascades
and the induction of pro-inflammatory cytokines.62
Although up-regulation of iNOS expression and NO
production during infection with M. tuberculosis is well
known, very few studies have actually identified the
M. tuberculosis proteins directly involved in the up-regu-
lation of the iNOS gene. Our study indicates that
rRv2626c affects the macrophage-signalling cascades and
up-regulates iNOS induction and NO production mainly
by increasing NF-jB activity. Interestingly, flow cytometry
data indicate that Rv2626c binds to the macrophage sur-
face with high affinity and specificity. It is possible that
the specific binding of Rv2626c on the macrophage sur-
face causes modulation of the downstream signalling
pathways triggering NF-jB signalling, which results in
increased induction of iNOS23 as well as the cytokines
TNF-a63 and IL-12.64 Although the exact beneficial role
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Figure 7. Recombinant Rv2626c (rRv2626c) increases the expression
of costimulatory molecules such as B7-1, B7-2 and CD40 in RAW
264.7 macrophages. RAW 2647 macrophages were treated with
rRv2626c at 3 lg/ml for 24 hr in the presence or absence of inter-
feron (IFN)-c and lipopolysaccharide (LPS). Cells were washed, incu-
bated with mouse anti-B7-1 (a), mouse anti-B7-2 (b) and mouse
anti-CD40 (c) and then incubated with anti-mouse fluorescein iso-
thiocyanate (FITC) conjugate. The control group received isotype
immunoglobulin G2a (IgG2a). This experiment is representative of
three experiments showing similar results.
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of iNOS/NO in anti-mycobacterial killing has not been
uniformly elucidated,65 studies have confirmed that
iNOS/NO is crucial in limiting bacterial growth.66,67 Simi-
larly, the role of TNF-a in TB is paradoxical because,
although there is evidence of its protective role,68 it can
play a part in the tissue damage that characterizes human
disease.68 A recent study also indicates that M. tuberculosis
activates TNF-a production to induce apoptosis of mac-
rophages.62
Our study clearly demonstrates that the secretory
M. tuberculosis Rv2626c protein induces pro-inflamma-
tory responses by modulating the expression of iNOS and
increasing the secretion of IL-12 and TNF-a, which may
play an important role in the initiation of the adaptive
immune response in the host. Mycobacterium tuberculosis
proteins that induce the Th1 response have been used as
targets for subunit vaccines. For example, use of the
mycobacterial 30-kDa major secretory protein (antigen
85B, Ag85B) was found to protect animals from M. tuber-
culosis infection by inducing a Th1-dominant response.69
Further, the recombinant BCG vaccine over-expressing
Ag85B also induced better protection against TB as com-
pared with the parental BCG strain;70 however, this was
not very successful in a phase 1 clinical trial. The hybrid
protein consisting of Mtb39 and Mtb32 (Mtb72F) was
also found to be immunogenic and produced an
enhanced Th1 response to BCG in mice but failed to
reduce the bacterial load in the lungs after an aerosol
challenge.71 Interestingly, the co-administration or boost-
ing of BCG vaccination with Mtb72F conferred protection
in both mouse and guinea pig models.71 Similar to
Rv2626c, the Rv1860 of M. tuberculosis also elicited both
a lymphoproliferative response and IFN-c production
from PBMCs, and the response was found to be different
in PPD-positive healthy controls and patients with pul-
monary TB;72 the protein also offered protection in gui-
nea pigs after M. tuberculosis challenge.
Rv2626c could also influence macrophage signalling for
induction of higher levels of B71 and B72 and CD-40
costimulatory molecules on the macrophage surface,
which may contribute to increased T-cell proliferation, as
observed in the in vitro T-cell proliferation assay. Priming
of T cells by expression of costimulatory molecules, MHC
molecules and the necessary cytokines is important for
T-cell polarization. Although some secretory proteins of
M. tuberculosis have been found to increase IL-12 produc-
tion and induce a pronounced Th1 response,73,74 to the
best of our knowledge, this is the first report showing that
Rv2626c can both activate costimulatory signalling and
trigger induction of the cytokines IL-12 and IFN-c. Thus,
Rv2626c may be a promising T-cell vaccine candidate.
The protective role of the Rv2626c protein was evident
from earlier studies showing that immunization of mice
with Rv2626c gave better protection against the bacilli
relative to the control.31 A detailed understanding of the
signalling pathway exploited by this protein will therefore
be helpful in designing better therapeutics against
M. tuberculosis.
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